Filter By Category
Archives
Share on -
AVALGLUCOSIDASE
Generic Name: AVALGLUCOSIDASE
ABSTRACT -
Avalglucosidase alfa is a recombinant human acid alpha-glucosidase enzyme replacement therapy designed to enhance mannose-6-phosphate receptor-mediated uptake for Pompe disease where approved. It is a glycoprotein biologic and has no single small-molecule skeletal structure. The representation above is an enzyme glycoprotein schematic.
This document is for structured API information only. It is not a prescribing guide. Clinical use, if any, must follow the approved local label, trial protocol, and specialist medical supervision.
DOSAGE -
- Dosage should be determined only by a qualified healthcare professional.
- Use only according to the approved local product label and institutional administration procedures.
- Infusion or injection settings must have monitoring and emergency support as required for the product class.
- Do not administer outside authorized indications or specialist supervision.
SIDE EFFECTS-
Possible side effects and safety concerns include:
- Infusion-associated reactions such as fever, chills, flushing, rash, or headache
- Nausea, vomiting, fatigue, myalgia, or abdominal discomfort
- Urticaria, pruritus, cough, or dyspnea during infusion
- Antibody formation may affect tolerability or response
- Serious hypersensitivity or anaphylaxis can occur
ALLERGIC REACTIONS -
Hypersensitivity to Avalglucosidase alfa or related compounds/products may occur. Symptoms may include:
- Immediate urticaria, itching, flushing, or generalized rash
- Facial, lip, tongue, or throat swelling
- Wheezing, chest tightness, or breathing difficulty
- Dizziness, fainting, severe hypotension, or collapse
- Anaphylaxis, although uncommon, requires emergency medical treatment
Important: Patients who develop an allergic reaction to Avalglucosidase alfa should seek immediate medical attention and inform all future healthcare providers of the allergy.
DRUG INTERACTIONS-
Avalglucosidase alfa may interact with certain medicines, biologics, vaccines, protocols, or clinical conditions. Caution is needed with:
- Other infused biologics may increase scheduling and monitoring complexity.
- Immunomodulating medicines may affect antibody response and infection risk.
- Premedication regimens should be managed by the treating specialist.
- Patients should inform providers about all medicines, vaccines, and supplements.
Patients should inform healthcare providers about all prescription medicines, over-the-counter medicines, herbal products, vaccines, and supplements they are using.
PREAUTIONS–
- Administer in a setting prepared to manage infusion reactions.
- Monitor respiratory and cardiac status in patients with advanced Pompe disease.
- Assess prior infusion reactions and anti-drug antibody history.
- Pregnancy and lactation require individualized specialist review.
WARNINGS –
- Life-threatening hypersensitivity and severe infusion reactions may occur.
- Interrupt or discontinue infusion if severe reactions develop.
- Use only under supervision familiar with enzyme replacement therapy.
- Keep out of reach of children.
Share on -
. Developed by